Identification of human cytochrome P450 isoforms involved in the metabolism of S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid

References

• BOURRIE M., MEUNIER, V., BERGER, Y. and FEBRE, G., 1996, Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 277, 321–332.
   Google Scholar
• BRAY, H. G. and CARPANINI, F. M. B., 1968, The metabolism of thiophene and benzo[b]thiophene. Biochemical Journal, 109, 11P.
   Google Scholar
• BRAY, H. G., CARPANINI, F. M. B. and WATERS, B. D., 1971, Metabolism of thiophene in the rabbit and the rat. Xenobiotica, 1, 157–168.
   Google Scholar
• CHAURET, N., GAUTHIER, A., MARTIN, J. and NicoLL, D. A., 1997, In vitro comparison ofcytochrome P450-mediated metabolic activities in human, dog, cat, and horse. Drug Metabolism and Disposition, 25, 1130–1136.
   PubMed Web of Science ®Google Scholar
• CHIBA, K., KOBAYASHI, K., MANABE, K., Ti, M., KAMATAKI, T. and ISHIZAKI, T., 1993, Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4--hydroxylation. Journal of Pharmacology and Experimental Therapeutics, 266, 52–59.
   PubMed Web of Science ®Google Scholar
• CHIBA, K., SAITO, A., CHIBA, T., ISHIZAKI, T., TANI, M., HAYASHI, M., MATUI M., SHIBA, K., KANEKO, H., NAKATUKA I., YABUSAKI, Y. and NAKAZAWA, H., 1994, Isoform(s) of cytochrome P450 responsible for the metabolism of nonsteroidal antiinflammatory drugs: oxidative metabolism of mefenamic acid and diclofenac by CYP2C subfamily. Yakubutudoutai, 9 (suppl.), S144–147.
   Google Scholar
• DAMANI, L. A. and CROOKS, P. A., 1982, Oxidative metabolism of heterocyclic ring systems. In W. B. Jakoby, J. R. Bend and J. Caldwell (eds) Metabolic Basis of Detoxication (New York: Academic Press), pp. 69–89.
   Google Scholar
• DE MORAIS, S. M. F., SCHWEIKL, H., BLAISDELL, J. and GOLDSTEIN, J. A., 1993, Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18. Biochemical and Biophysical Research Communications, 194, 194–201.
   Google Scholar
• FRANKLIN, M. R., 1977, Inhibition of mixed-function oxidations by substrates forming reduced cytochrome P-450 metabolic-intermediate complexes. Pharmacology and Therapeutics, A, 2, 227–245.
   Web of Science ®Google Scholar
• Goinsmav, J. A. and DE MORAIS, S. M. F., 1994, Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics, 4, 285–299.
   PubMedGoogle Scholar
• GONZALEZ, F. J., 1992, Human cytochrome P450: problems and prospects. Trends in Pharmacological Science, 13, 346–352.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., 1993, The 1992 Bernard B. Brodie Award Lecture: Bioactivation and detoxication of toxic and carcinogenic chemicals. Drug Metabolism and Disposition, 21, 1–6.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., 1994, Catalytic selectivity of human cytochrome P450: relevance to drug metabolism and toxicity. Toxicology Letters, 70, 133–138.
   PubMed Web of Science ®Google Scholar
• IWATSUBO, T., HIROTA, N., 001E, T., Suzum, H. and SUHIYAMA, Y., 1996, Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharmaceutks and Drug Disposition, 17, 273–310.
   Google Scholar
• KATAOKA, M., TONOOKA, K., ANDO, T., him, K. and AIMOTO, T., 1997, Hydroxyl radical scavenging activity of nonsteroidal anti-inflammatory drugs. Free Radical Research, 27, 419–427.
   PubMed Web of Science ®Google Scholar
• Kroo, H., MURAKAW, N., IT0, A., KIMURA, K., KODERA, N., Doi, T. and NARUSE, T., 1998, Anti-inflammatory, analgesic and anti-pyretic effects of d-244-(3-methyl-2-thienyl)phenyl]propionic acid (M-5011), a new non-steroidal anti-inflammatory drug, in rats and guinea pigs. japan journal of Pharmacology, 76, 75–86.
   Google Scholar
• Ko, J. W., SUKHOVA, N., THACKER, D., CH, P. and FLOCKHART, D. A., 1997, Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metabolism and Disposition, 25, 853–862.
   PubMed Web of Science ®Google Scholar
• KONISHI, T., OKADA, S., NISHIKAWA, H., Esuivi[, Y., KITAIVIURA, S. and TATSUMI, K., 1998, Disposition of a new nonsteroidal anti-inflammatory agent, S-244-(3-methyl-2-thienyl)phenyl]propionic acid, in rats, dogs and monkeys. Arzneimittel-Forschung/ Drug Research, 48, 266–274.
   Google Scholar
• KONISHI, T., NISHIKAWA, H., KITAMURA, S. and TATSUMI, K., 1999, In vivo studies on chiral inversion and amino acid conjugation of 2 -[4-(3-methyl-2-thienyl)phenyl]propionic acid in rats and dogs. Drug Metabolism and Disposition, 27, 158–160.
   PubMedGoogle Scholar
• LEEMANN, T., TRANSON, C. and DAYER, P., 1992, Cytochrome CYP450TB(CYP2C): a major monooxygenase catalyzing diclofenac 4--hydroxylase in human liver. Life Sciences, 52, 29–34.
   Google Scholar
• LEWIS, D. F. V., 1998, The CYP2 family: models, mutants and interactions. Xenobiotica, 28, 617–661.
   PubMed Web of Science ®Google Scholar
• LEWIS, D. F. V., DiciuNs, M., WEAVER, R. J., EDDERSHAW, P. J., GOLDFARB, P. S. and TARBrr, M. H., 1998, Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily. Xenobiotica, 28, 235–268.
   Google Scholar
• MURAKAW, N., TAKASE, H., IWATA, K. and NARUSE, T., 1996, Antinociceptive activity of novel non-steroidal anti-inflammatory drug (M-5011) with low ulcerogenic effects in mice. japan journal of Pharmacology, 72, 29–37.
   PubMedGoogle Scholar
• NEWTON, D. J., WANG, R. W. and Lu, Y. H., 1995, Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154-158. PARKINSON, A., 1996, An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicologic Pathology, 24, 45–57.
   Google Scholar
• RENDIC S. and Di CARLO, F. J., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metabolism Reviews, 29, 413–580.
   PubMed Web of Science ®Google Scholar
• REITIE, A. E., WIENKERS, L. C., GONZALEZ, F. J., TRAGER, W. F. and KORZEKWA, K. R., 1994, Impaired (S)-warfarin metabolism catalyzed by the R144C allelic variant of CYP2C9. Pharmacogenetics, 4, 39–42.
   PubMedGoogle Scholar
• SHAH, V. P., MIDHA, K. K., DIGHE S. I., MCGILVERAY, J., SKELLY, J. P., YACOBI, A., LAYLOFF, T., VISWANATHAN, C. T., COOK, C. E., McDowALL, R. D., PIITIVIAN, K. A. and SPECTOR, S., 1992, Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Journal of Pharmaceutical Sciences, 81, 309–314.
   Google Scholar
• SHEVIADA, T., YAIVIAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414–423.
   PubMed Web of Science ®Google Scholar
• SmiTH, D. A., 1991, Species differences in metabolism and pharmacokinetics : are we close to an understanding? Drug Metabolism Reviews, 23, 355–373.
   PubMed Web of Science ®Google Scholar
• SmiTH, D. A. and JONES, B. C., 1992, Speculations on the substrate structure—activity relationship (SSAR) of cytochrome P450 enzymes. Biochemical Pharmacology, 44, 2089–2098.
   PubMed Web of Science ®Google Scholar
• TOBEITO, K., YAMAMOTO, Y., KATAOKA, M., ANDO, T., SUGIMOTO, K. and HIIVIENO, M., 1997, The effects of a newly developed nonsteroidal anti-inflammatory drug (M-5011) on arachidonic acid metabolism in rheumatoid synovial fibroblasts. Japan Journal of Pharmacology, 75, 371–379.
   PubMedGoogle Scholar
• VERONESE, M. E., MACKENZIE, P. I., DOECKE C. J., McMANus, M. E., MINERS, J. 0. and BIRKEIT D. J., 1991, Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cyto-chrome P 4502C9. Biochemical and Biophysical Research Communications, 175, 1112–1118.
   Google Scholar
• VERONESE, M. E., DOECKE C. J., MACKENZIE, P.1., MCMANUS, M. E., MINERS, J. 0., REES, D. L. P., GASSER, R., MEYER, U. A. and BIRKETT, D. J., 1993, Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochemical Journal, 289, 533–538.
   Google Scholar
• YAIVIAZAKI, H., INouE, K. and SHEVIADA, T.,1998, Role of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolubutamide and warfarin by human liver microsomes. Xenobiotica, 28, 103–115.
   Google Scholar
• YASUMORI, T., NAGATA, K., YANG, S. K., CHEN, L. S., MURAYAIVIA, N., YAIVIAZOE, Y. and KATO, R., 1993, Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. Pharmaco-genetics, 3, 291–301.
   PubMedGoogle Scholar